StackPath Propel Startup Program Celebrates One Year Anniversary
Adds Even More Resources and Mentorship for the Early and Growth Stage Tech Community
DALLAS, Sept. 04, 2018 (GLOBE NEWSWIRE) -- One year ago StackPath, the world’s only secure edge platform, launched StackPath Propel, a program that provides resources, insight, and expert advice to early-stage companies at no cost to them.
“It’s been part of StackPath culture since day one to support the startup community and it was a great year for Propel. In the past 12 months more than 100 startups from five continents have been accepted into the program,” said James Leaverton, VP Ecosystems. “We’ve helped a lot, we’ve learned a lot, and now want to increase our offerings so we can help even more—when one startup succeeds we all learn and succeed with them.”
Since launch, Propel has provided its members with secure content delivery network (CDN) and virtual private network (VPN) services free for one year. Starting today, Propel members may receive free for one year up to $2,000/month of usage of all the new and updated services that StackPath launched when it released its next-generation platform in July 2018, including website monitoring, web application firewall (WAF), managed DNS, and updated CDN and VPN services. Usage details include:
- 100TB/month CDN bandwidth
- 5 VPN licenses
- 50M/month WAF requests
- 20 WAF rules
- 10M/month DNS requests
- 10 monitored services
- Unlimited CDN & WAF Sites
- Unlimited CDN requests
- Unlimited CDN EdgeRules
- Origin Shield Included
- DDoS Protection Included
- SSL Included
In addition, the StackPath ecosystems team will continue to share with Propel members its startup insight and expertise. Everything from making strategic introductions to talent, investors, and peers, to brainstorming business practices, to reviewing pitch decks, StackPath Propel was created to help new companies with what they need to grow and thrive.
“StackPath Propel provides the rare combination of expert resources and accessibility, and it transformed our company,” said Matt Waite, Founder of Apres.io. “We worked together on several key issues that scaled our business, and I was impressed with StackPath’s ability to translate difficult, early stage problems into tailored solutions. The resources and services they offer show their understanding of early stage needs and have been impactful beyond the bottom line. Propel would be an asset to any early stage startup.”
“I have been continuously impressed with the entire StackPath ecosystem team,” stated Dylan Boyd, Director R/GA Ventures. “One of the best things about working with StackPath is their dedication to our ecosystem of entrepreneurs and founders. Their innate ability to help with so many issues founders face every day is rare to find. As founders themselves, and successful ones at that, we are fortunate to have partners as dedicated and able as StackPath.”
To learn more about StackPath Propel and how you too can partner, visit https://www.stackpath.com/resources/propel-startup-program/.
Protect your edge.™
StackPath is a platform of secure edge services that enables developers to protect, accelerate, and innovate cloud properties ranging from websites to media delivery and IoT services. With an innovative global edge network infrastructure, StackPath delivers enterprise-grade security and performance in a frictionless, on-demand platform with cloud-scale control and flexibility. More than one million customers, including early-stage and Fortune 100 companies, use StackPath services. StackPath is headquartered in Dallas and has offices across the U.S. and around the world. For more information, visit stackpath.com and follow StackPath at www.fb.com/stackpathllc and www.twitter.com/stackpath .
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg saker fra GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra GlobeNewswire
WillScot to Participate at the Barclays Industrial Select Conference16.1.2019 21:00 | Pressemelding
BALTIMORE, Jan. 16, 2019 (GLOBE NEWSWIRE) -- WillScot Corporation (“WillScot”)(NASDAQ: WSC), the specialty rental services market leader providing innovative modular space and portable storage solutions across North America, today announced that Brad Soultz, President and Chief Executive Officer, and Tim Boswell, Chief Financial Officer, will present at the Barclays Industrial Select Conference at the Loews Miami Beach Hotel in Miami, Florida, on Wednesday, Feb. 20, 2019. The presentation will take place at 10:20 a.m. EST. About Williams Scotsman Headquartered in Baltimore, Maryland, WillScot Corporation is the public holding company for the WillScot family of companies in the United States, Canada and Mexico. WillScot Corporation trades on the NASDAQ stock exchange under the ticker symbol “WSC.” WillScot is the specialty rental services market leader providing innovative modular space and portable storage solutions across North America. It is the modular space supplier of choice for t
CCI has been retained by Waterloo Brewing to obtain Cannabis Licence16.1.2019 16:00 | Pressemelding
TORONTO, Jan. 16, 2019 (GLOBE NEWSWIRE) -- Cannabis Compliance Inc., (CCI) of Toronto, Ontario is pleased to announce they have partnered with Waterloo Brewing to help them obtain their Research and standard Processing Licence to develop cannabis-infused beverages. “CCI is working with Waterloo Brewing on the early stages of the application process and we are confident that we will help them achieve their desired licenses in time to be an active player in this growing sector of the cannabis industry”, said Brian Wagner, CEO and Founder, Cannabis Compliance Inc. “We are here to guide our clients through the early stages of the licensing process and for the many Health Canada requirements thereafter.” CCI offers end to end business solutions for cannabis companies large and small. Our team brings with them years of experience in the quality, regulatory, security and cultivation sectors, and supports manufacturers and retailers through regulatory challenges. As the world’s largest and mos
Aryaka Announces Expansion of Senior Leadership Team with New Chief Revenue Officer, Chief Transformation Officer and Chief Marketing Officer16.1.2019 15:00 | Pressemelding
Karen Freitag, Michelle Owczarzak, & Shashi Kiran join Aryaka to address significant growth and assist global enterprises in adopting managed connectivity as-a-service SAN MATEO, Calif., Jan. 16, 2019 (GLOBE NEWSWIRE) -- Aryaka®, announced today the appointment of several new executive hires to the company’s leadership team, including Karen Freitag (Chief Revenue Officer), Michelle Owczarzak (Chief Transformation Officer), and Shashi Kiran (Chief Marketing Officer). “Connectivity is the lifeblood of the global enterprise and Aryaka is the industry benchmark for secure managed connectivity worldwide. We are excited to have experienced industry veterans join our robust executive leadership team and continue to help build upon the immense success and growth that Aryaka has seen in recent years,” said Matt Carter, CEO of Aryaka. “As our customers expand globally, embrace SD-WAN, or move to the cloud, we’re becoming the de facto choice for their needs to make this happen better, faster, che
ADC Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ADCT-601 in Advanced Solid Tumors16.1.2019 07:00 | Pressemelding
Pyrrolobenzodiazepine-based antibody drug conjugate targets AXL, a receptor tyrosine kinase highly expressed in solid tumors LAUSANNE, Switzerland, Jan. 16, 2019 (GLOBE NEWSWIRE) -- ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of proprietary antibody drug conjugates (ADCs), today announced that the first patient has been dosed in its Phase I clinical trial evaluating the safety, tolerability, pharmacokinetics and anti-tumor activity of ADCT-601 in patients with selected solid tumors that are locally advanced or metastatic. ADCT-601 is an ADC composed of a humanized monoclonal antibody against human AXL, conjugated using GlycoConnect™ site specific conjugation technology to a pyrrolobenzodiazepine (PBD) dimer toxin. In preclinical studies, ADCT-601 demonstrated potent and specific in vitro and in vivo anti-tumor activity in multiple cancer-derived models with different levels of AXL expression, and was stable and well tolerated
GSA Europe’s Managing Director Elected Co-lead of CEN’s TC456 Committee15.1.2019 21:12 | Pressemelding
SAN GWANN, Malta, Jan. 15, 2019 (GLOBE NEWSWIRE) -- GSA Europe’s Managing Director Mark Pace has been elected by the Comité Européen de Normalisation (CEN) to lead the creation of a European Union online gaming reporting standard. CEN has established Technical Committee 456 to create this standard in support of online gambling supervision. GSA Europe joined Technical Committee 456 as a Liaison Organization in 2017. The Technical Committee’s mandate from the European Commission is directly aligned with work that GSA Europe has already started, namely, to create a single standard set of data elements and single standard way in which data is provided by online gambling providers to EU Member State regulatory authorities. In addition to joining and now leading the Technical Committee’s work, GSA Europe also donated their draft Regulatory Data Set and Regulatory Reporting Interface to CEN seeking to help jump-start the Committee’s work. “Joining CEN’s TC456 as a Liaison Organization, and no
Orion Biotechnology Reports Positive Results for Colorectal Cancer in Preclinical Study15.1.2019 15:00 | Pressemelding
OTTAWA, Jan. 15, 2019 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd., a developer of novel medical treatments, today announced preclinical data produced in collaboration with Charles River Laboratories, evaluating the efficacy of OB-002O (5P12-RANTES) in colorectal cancer. BALB/c mice were inoculated subcutaneously with the CT-26 colorectal cancer cell line. Three days after inoculation intraperitoneal treatment was started with OB-002O, a murine anti-PD-1 antibody, OB-002 + anti-PD-1, or saline placebo. Treatment was given daily or every third day. Treatment with OB-0020 alone led to statistically significant delayed tumor growth at multiple time-points. An even more profound effect on the decrease in mean tumor volume was observed in combination cohort where animals received both, OB-0020 and the anti-PD-1 antibody (p>0.05). “There is growing awareness of the role of CCR5 antagonism as an important component of cancer immunotherapy. OB-002O is an extremely potent CCR5 antagonist